title: Why should results from metastatic trials no longer matter for early-stage disease?
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Dieudonné
authors.forename: Diether
authors.initials: D
authors.lastname: Lambrechts
authors.forename: Hans
authors.initials: H
authors.lastname: Wildiers
authors.forename: Patrick
authors.initials: P
authors.lastname: Neven
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005260:Female; D006801:Humans; D017698:Postmenopause / Q000235:genetics*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6